The standard treatment triplet has been proven to have a significant survival advantage in comparison with a doublet without epirubicin. No directly comparative studies are available which prove the effectiveness of tegafur/gimeracil/oteracil in comparison with the standard treatment.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.